Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228992 · ClinicalTrials.gov registry record · Phase 4
Ibuprofen Versus Placebo For Muscle Soreness
A Phase 4 study of Muscle Soreness, sponsored by Jean Brown Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03228992 is a Phase 4 study of Muscle Soreness that has completed, run by Jean Brown Research. The registered enrollment target is 31 participants, roughly in line with the 30-participant average among 4 other Muscle Soreness trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03228992, a Phase 4 study of Muscle Soreness, has completed, sponsored by Jean Brown Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ibuprofen 400 mg
Study Locations (1)
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-04-10 |
| Est. Completion | 2017-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228992
The ClinicalTrials.gov registry entry for NCT03228992 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 30-participant average among 4 other Muscle Soreness trials with a reported enrollment target. The listed sponsor is Jean Brown Research, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle Soreness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03228992 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT03228992 about?
NCT03228992 is a clinical study titled "Ibuprofen Versus Placebo For Muscle Soreness". The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.
What is the current status of trial NCT03228992?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2017-04-10. Estimated completion is 2017-07-31.
What conditions does trial NCT03228992 study?
This clinical trial studies the following conditions: Muscle Soreness.
What interventions are being tested in trial NCT03228992?
The interventions under investigation include: Placebo (OTHER), Ibuprofen 400 mg (DRUG).
Who is sponsoring clinical trial NCT03228992?
This trial is sponsored by Jean Brown Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03228992 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Soreness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.